{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:14Z","timestamp":1793465534436,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006392","name":"CHUV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1093\/annonc\/mdz398","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T07:25:50Z","timestamp":1569482750000},"page":"1902-1913","source":"Crossref","is-referenced-by-count":255,"title":["Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-5419","authenticated-orcid":false,"given":"U","family":"Dafni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Michielin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Martin","family":"Lluesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Tsourti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Polydoropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Karlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Besser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I -M","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P S","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U S","family":"Kammula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Orcurto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Trueb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Klebanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Lotze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L E","family":"Kandalaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.125.1.238","article-title":"In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors","volume":"125","author":"Yron","year":"1980","journal-title":"J Immunol"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-3083.1997.d01-384.x","article-title":"Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes","volume":"45","author":"Maeurer","year":"1997","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000111","article-title":"Expansion of tumor-reactive T cells from patients with pancreatic cancer","volume":"39","author":"Meng","year":"2016","journal-title":"J Immunother"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0025","doi-asserted-by":"crossref","first-page":"e1252894","DOI":"10.1080\/2162402X.2016.1252894","article-title":"Tumor-infiltrating lymphocytes (TILs) from patients with glioma","volume":"6","author":"Liu","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6184","key":"10.1093\/annonc\/mdz398_bb0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"25","key":"10.1093\/annonc\/mdz398_bb0035","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0040","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"issue":"15","key":"10.1093\/annonc\/mdz398_bb0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-1759(87)80018-2","article-title":"Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials","volume":"102","author":"Topalian","year":"1987","journal-title":"J Immunol Methods"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdz398_bb0060","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0065","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdz398_bb0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","article-title":"Establishment and large-scale expansion of minimally cultured \u201cyoung\u201d tumor infiltrating lymphocytes for adoptive transfer therapy","volume":"34","author":"Itzhaki","year":"2011","journal-title":"J Immunother"},{"issue":"7","key":"10.1093\/annonc\/mdz398_bb0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8(+) T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdz398_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4049\/jimmunol.115.1.234","article-title":"Syngeneic adoptive immunotherapy and chemoimmuno-therapy of a friend leukemia: requirement for T cells","volume":"115","author":"Berenson","year":"1975","journal-title":"J Immunol"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"issue":"4770","key":"10.1093\/annonc\/mdz398_bb0090","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0095","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1093\/annonc\/mdz398_bb0100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","article-title":"A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma","volume":"25","author":"Dudley","year":"2002","journal-title":"J Immunother"},{"issue":"5594","key":"10.1093\/annonc\/mdz398_bb0105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"issue":"9","key":"10.1093\/annonc\/mdz398_bb0110","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","article-title":"Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients","volume":"16","author":"Besser","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1093\/annonc\/mdz398_bb0115","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","article-title":"CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma","volume":"16","author":"Dudley","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"issue":"24","key":"10.1093\/annonc\/mdz398_bb0125","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdz398_bb0130","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdz398_bb0135","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","article-title":"Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma","volume":"31","author":"Dudley","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz398_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-S3-P1","article-title":"Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma","volume":"2","author":"Andersen","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1093\/annonc\/mdz398_bb0145","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1093\/annonc\/mdz398_bb0150","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdz398_bb0155","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-17-3649","article-title":"Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome","volume":"24","author":"Forget","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz398_bb0160","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mdz398_bb0165","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"12","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7109","key":"10.1093\/annonc\/mdz398_bb0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0175","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Method"},{"issue":"3","key":"10.1093\/annonc\/mdz398_bb0185","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"Pt A","key":"10.1093\/annonc\/mdz398_bb0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"issue":"7414","key":"10.1093\/annonc\/mdz398_bb0195","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00262-011-1182-4","article-title":"Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy","volume":"61","author":"Ullenhag","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1093\/annonc\/mdz398_bb0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/CJI.0b013e31826e8f5f","article-title":"Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma","volume":"35","author":"Pilon-Thomas","year":"2012","journal-title":"J Immunother"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CJI.0000000000000223","article-title":"Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases","volume":"41","author":"Mehta","year":"2018","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdz398_bb0215","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdz398_bb0220","first-page":"Mr000007","article-title":"Individual participant data meta-analyses compared with meta-analyses based on aggregate data","volume":"9","author":"Tudur Smith","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1093\/annonc\/mdz398_bb0225","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz398_bb0230","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0235","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1084\/jem.20081382","article-title":"Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response","volume":"206","author":"Rizzuto","year":"2009","journal-title":"J Exp Med"},{"issue":"9","key":"10.1093\/annonc\/mdz398_bb0240","doi-asserted-by":"crossref","first-page":"e1326442","DOI":"10.1080\/2162402X.2017.1326442","article-title":"Local endothelial complement activation reverses endothelial quiescence, enabling T-cell homing, and tumor control during T-cell immunotherapy","volume":"6","author":"Facciabene","year":"2017","journal-title":"Oncoimmunology"},{"issue":"16","key":"10.1093\/annonc\/mdz398_bb0245","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","article-title":"Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice","volume":"17","author":"Klebanoff","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1093\/annonc\/mdz398_bb0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0260","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz398_bb0270","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.2019.37.15_suppl.2518","article-title":"Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1","volume":"37","author":"Sarnaik","year":"2019","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz398_bb0275","doi-asserted-by":"crossref","first-page":"e14024","DOI":"10.1200\/JCO.2019.37.15_suppl.e14024","article-title":"Treatment with tumor-infiltrating lymphocytes in the changing treatment landscape of metastatic melanoma","volume":"37","author":"Borch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7528","key":"10.1093\/annonc\/mdz398_bb0280","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdz398_bb0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv Immunol"},{"issue":"24","key":"10.1093\/annonc\/mdz398_bb0290","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1093\/annonc\/mdz398_bb0295","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1093\/annonc\/mdz398_bb0300","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0305","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0310","doi-asserted-by":"crossref","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdz398_bb0315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1172\/JCI114984","article-title":"Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression","volume":"87","author":"D'Urso","year":"1991","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"10.1093\/annonc\/mdz398_bb0325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdz398_bb0330","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CJI.0000000000000245","article-title":"Treatment with tumor-infiltrating lymphocytes in advanced melanoma: evaluation of early clinical implementation of an advanced therapy medicinal product","volume":"41","author":"Lindenberg","year":"2018","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdz398_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00345","article-title":"Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination","volume":"7","author":"Redeker","year":"2016","journal-title":"Front Immunol"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0340","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdz398_bb0345","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","article-title":"Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes","volume":"110","author":"Quintarelli","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0350","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/hum.2007.0171","article-title":"Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2","volume":"19","author":"Heemskerk","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"18","key":"10.1093\/annonc\/mdz398_bb0355","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1093\/annonc\/mdz398_bb0360","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.4049\/jimmunol.175.11.7226","article-title":"Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine","volume":"175","author":"Hsu","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"10.1093\/annonc\/mdz398_bb0365","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz398_bb0370","doi-asserted-by":"crossref","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz398_bb0375","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2017.35.15_suppl.2545","article-title":"Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy","volume":"35","author":"Bernatchez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"80","key":"10.1093\/annonc\/mdz398_bb0380","doi-asserted-by":"crossref","first-page":"80ra34","DOI":"10.1126\/scitranslmed.3002207","article-title":"Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells","volume":"3","author":"Butler","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1093\/annonc\/mdz398_bb0385","doi-asserted-by":"crossref","first-page":"e3289","DOI":"10.1371\/journal.pone.0003289","article-title":"Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells","volume":"3","author":"Carroll","year":"2008","journal-title":"PLoS One"},{"issue":"10","key":"10.1093\/annonc\/mdz398_bb0390","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0395","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab"},{"key":"10.1093\/annonc\/mdz398_bb0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.03.011","article-title":"Metabolic reprograming of anti-tumor immunity","volume":"46","author":"Sukumar","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1093\/annonc\/mdz398_bb0405","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1158\/0008-5472.CAN-14-2277","article-title":"Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics","volume":"75","author":"Crompton","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mdz398_bb0410","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0415","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1038\/ncomms7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat Commun"},{"issue":"7621","key":"10.1093\/annonc\/mdz398_bb0420","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"issue":"6434","key":"10.1093\/annonc\/mdz398_bb0425","doi-asserted-by":"crossref","first-page":"eaau0135","DOI":"10.1126\/science.aau0135","article-title":"T cell stemness and dysfunction in tumors are triggered by a common mechanism","volume":"363","author":"Vodnala","year":"2019","journal-title":"Science"},{"key":"10.1093\/annonc\/mdz398_bb0430","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"issue":"7596","key":"10.1093\/annonc\/mdz398_bb0435","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature17412","article-title":"Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism","volume":"531","author":"Yang","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1093\/annonc\/mdz398_bb0440","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"issue":"6382","key":"10.1093\/annonc\/mdz398_bb0445","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1093\/annonc\/mdz398_bb0450","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.4049\/jimmunol.175.6.3534","article-title":"OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen","volume":"175","author":"Song","year":"2005","journal-title":"J Immunol"},{"issue":"7","key":"10.1093\/annonc\/mdz398_bb0455","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"Zhang","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0460","doi-asserted-by":"crossref","first-page":"e60031","DOI":"10.1371\/journal.pone.0060031","article-title":"Co-stimulation through 4-1BB\/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"8","author":"Chacon","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1093\/annonc\/mdz398_bb0465","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CJI.0b013e318209e7ec","article-title":"Co-stimulation through the CD137\/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances anti-tumor effector function","volume":"34","author":"Hernandez-Chacon","year":"2011","journal-title":"J Immunother"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0470","doi-asserted-by":"crossref","first-page":"e0126765","DOI":"10.1371\/journal.pone.0126765","article-title":"4-1BB signaling enhances primary and secondary population expansion of CD8+ T cells by maximizing autocrine IL-2\/IL-2 receptor signaling","volume":"10","author":"Oh","year":"2015","journal-title":"PLoS One"},{"issue":"6257","key":"10.1093\/annonc\/mdz398_bb0475","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"6230","key":"10.1093\/annonc\/mdz398_bb0480","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunobiology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"32","key":"10.1093\/annonc\/mdz398_bb0485","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"issue":"39","key":"10.1093\/annonc\/mdz398_bb0490","doi-asserted-by":"crossref","first-page":"42334","DOI":"10.18632\/oncotarget.5997","article-title":"Mutational profiling of colorectal cancers with microsatellite instability","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1093\/annonc\/mdz398_bb0495","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdz398_bb0500","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"10.1093\/annonc\/mdz398_bb0505","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdz398_bb0510","series-title":"bioRxiv","article-title":"Evolutionary dynamics of neoantigens in growing tumours","author":"Lakatos","year":"2019"},{"issue":"16","key":"10.1093\/annonc\/mdz398_bb0515","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"22","key":"10.1093\/annonc\/mdz398_bb0520","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","article-title":"Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses","volume":"16","author":"Peng","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdz398_bb0525","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gt.2012.75","article-title":"Inhibition of TGF-\u03b2 signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy","volume":"20","author":"Zhang","year":"2013","journal-title":"Gene Ther"},{"issue":"4","key":"10.1093\/annonc\/mdz398_bb0530","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","article-title":"T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy","volume":"129","author":"Yamamoto","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdz398_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00908","article-title":"A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes","volume":"8","author":"Forget","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0540","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","article-title":"Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics","volume":"7","author":"Guo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz398_bb0545","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1093\/annonc\/mdz398_bb0550","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"issue":"46","key":"10.1093\/annonc\/mdz398_bb0555","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"10.1093\/annonc\/mdz398_bb0560","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/1078-0432.CCR-17-0944","article-title":"Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I\u2212II melanoma: data from two randomized phase II trials","volume":"23","author":"Koster","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1093\/annonc\/mdz398_bb0565","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420325539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz398\/30132208\/mdz398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/12\/1902\/31637454\/mdz398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/12\/1902\/31637454\/mdz398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T18:44:11Z","timestamp":1695235451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420325539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":112,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0923753420325539"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz398","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}